Organization
Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
1 abstract
Abstract
Efficacy, safety, and biomarkers of neoadjuvant niraparib monotherapy in homologous recombination deficiency (HRD) advanced ovarian cancer: A prospective, multicenter, phase II, single-arm NANT study.Org: Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, China, Department of Gynecological Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Shandong University, Jinan, China,